ClinicalTrials.gg
TerminatedNCT05443724Updated Aug 21, 2026Results posted

A Study to Evaluate Safety and Tolerability of CVL-231 (Emraclidine) in Adult Participants With Schizophrenia

A Phase 2 interventional study of Emraclidine 30 mg in Schizophrenia, sponsored by AbbVie. Terminated at 85 sites in 5 countries. Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2026-08-21.

Sponsored by AbbVie · Phase 2, Interventional, and Treatment

Why this study was terminated
The study was terminated due to business reasons, not safety reasons.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
698
Allocation
Not applicable
Ages
18 Years to 65 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 27 studies in Schizophrenia by AbbVie — 1 open to participants now, 1 under way, none of them phase 3. Schizophrenia · AbbVie.

Enrollment
4th of 27
698 · median 268
Started
2022
with 4 others
Phase 2
13 of 27
1 open now
Registered
26th of 27
by date

Among the 27 studies in Schizophrenia by AbbVie, this one is the 4th largest by enrollment, is one of 5 that started in 2022, is one of 13 in phase 2, and was the 26th registered.

Schizophrenia

3,571 studies on the registry are indexed under Schizophrenia; 494 are open to participants now.

Browse Schizophrenia studies →

Open to participants now

1 of the 27 studies in Schizophrenia by AbbVie is open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

Who these studies take

Of the 333 Schizophrenia studies recruiting now, 63 (19%) set no upper age limit and 258 (77%) stop at 75 or younger; 42 take children under 18; 83 take healthy volunteers.

This study: 18 Years to 65 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 27 studies in Schizophrenia by AbbVie, or all of them as a file.
02

Study summary

The primary purpose of this study is to assess the long-term safety and tolerability of oral emraclidine in adult participants with schizophrenia.

03

Conditions studied

  • Schizophrenia

Keywords

  • Schizophrenia Spectrum and Other Psychotic Disorders
  • Mental Disorders
04

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Completed 6 weeks of post-randomization treatment in Trial CVL-231-2001 (NCT05227690) or CVL-231-2002 (NCT05227703) and who, in the opinion of the investigator, could potentially benefit from treatment with emraclidine for schizophrenia.
  2. Primary diagnosis of schizophrenia per , Fifth Edition (DSM-5), as confirmed by the Mini International Neuropsychiatric Interview (MINI) for Psychotic Disorders.
  3. Participants who have been stable on antipsychotic medication for at least one 3-month in the year prior to screening.
  4. Outpatient status at the time of signing the form informed consent form (ICF).
  5. Willing to discontinue all prohibited medications to meet protocol-required washouts prior to and during the trial period.
  6. Ability, in the investigator's opinion, to understand the nature of the trial, participate in trial visits, and comply with protocol requirements.

Exclusion criteria

Exclusion Criteria:

  1. Current diagnosis other than schizophrenia (note: anxiety symptoms secondary to schizophrenia are allowed.

    • Acute depressive symptoms within 30 days prior to signing the ICF that require treatment with an antidepressant are exclusory.
    • Acute manic symptoms within 30 days prior to signing the ICF that require treatment with a mood stabilizer are exclusory.
  2. Any of the following:

    • Schizophrenia is considered resistant/ to antipsychotic treatment by history (failure to respond to 2 or more courses of adequate pharmacological treatment defined as an adequate dose per label and a treatment duration of at least 4 weeks).
    • History of response to clozapine treatment only or failure to respond to clozapine treatment.
  3. Current or past history of significant cardiovascular, pulmonary, gastrointestinal, renal, hepatic, metabolic, genitourinary, endocrine (including diabetes mellitus), (except for basal cell carcinoma of the skin and cervical carcinoma in situ, at the discretion of the investigator), hematological, immunological, neurological, or psychiatric disease that, in the opinion of the investigator or medical monitor, could compromise either participant safety or the results of the trial.
  4. Active central nervous system infection, demyelinating disease, degenerative neurological disease, brain tumor, prior hospitalization for severe head trauma, seizures (excluding febrile seizures in childhood), or any central nervous system disease deemed to be progressive during the trial that may confound the interpretation of the trial results
  5. Diagnosis of moderate to severe substance or alcohol use disorder (excluding nicotine or caffeine) as per DSM-5 criteria within 12 months prior to signing the ICF.
  6. Risk for suicidal behavior as assessed by the C-SSRS and investigator's clinical assessment.
  7. Any condition that could possibly affect drug absorption, including, but not limited to bowel resections, bariatric weight loss surgery, gastric banding, and gastrectomy
  8. Use of prohibited medications prior to randomization within the required or likely to require prohibited concomitant therapy during the trial.
  9. abnormal findings on the physical examination, medical history review, , or clinical laboratory results at screening.
  10. Positive pregnancy test result prior to receiving medicinal product (IMP).

Note: female participants who are pregnant, breastfeeding, or planning to become pregnant during IMP treatment or within 7 days after the last dose of the IMP are also excluded.

Terms in these criteria, in plain language(8)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

DSM diagnostic criteria

The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Relapsed and refractory

Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Washout period

A planned gap after a treatment, so that its effects can lessen before the study treatment or a study assessment. Ask the study team and the doctor who prescribed it before changing any medicine.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
698 participants (actual)

Study arms

  • Experimental
    CVL-231-2001/2002 Active Rollover

    Participants who completed treatment with emraclidine in one of the double-blind, placebo-controlled Phase 2 efficacy trials (CVL-231-2001; NCT05227690 or CVL-231-2002; NCT05227703) were denoted as "active rollover" participants. They received emraclidine 30 mg tablets orally once daily (QD) for 52 weeks in this study.

    Drug: Emraclidine 30 mg

  • Experimental
    CVL-231-2001/2002 Placebo Rollover

    Participants who completed treatment with placebo for emraclidine in one of the double-blind, placebo-controlled Phase 2 efficacy trials (CVL-231-2001; NCT05227690 or CVL-231-2002; NCT05227703) were denoted as "placebo rollover" participants. They received emraclidine 30 mg tablets orally once daily (QD) for 52 weeks in this study.

    Drug: Emraclidine 30 mg

  • Experimental
    De Novo

    Participants with stable schizophrenia who were not enrolled in one of the prior Phase 2 efficacy trials were denoted as "de novo" participants. They received emraclidine 30 mg tablets orally once daily (QD) for 52 weeks in this study.

    Drug: Emraclidine 30 mg

Interventions

  • Emraclidine 30 mg, oral (tablet), once per day for 52 weeks

    Also known as: CVL-231, ABBV-1231

06

What researchers measure

Primary outcomes

  1. Number of Participants With Treatment Emergent Adverse Events (TEAEs) and Treatment Emergent Serious Adverse Events (TESAEs)

    An adverse event (AE) is defined as any untoward medical occurrence in a patient or clinical investigation participant administered a pharmaceutical product which does not necessarily have a causal relationship with this treatment. The investigator assesses the relationship of each event to the use of study drug. A serious adverse event (SAE) is an event that results in death, is life-threatening, requires or prolongs hospitalization, results in a congenital anomaly, persistent or significant disability/incapacity or is an important medical event that, based on medical judgment, may jeopardize the participant and may require medical or surgical intervention to prevent any of the outcomes listed above. Treatment-emergent adverse events/treatment-emergent serious adverse events (TEAEs/TESAEs) are defined as any event that began or worsened in severity on or after the first dose of study drug.

    Time frame: From first dose of study drug until 28 days following last dose of study drug (up to Week 56)

  2. Number of Participants With Out-of-Range Vital Signs Occurring Post-Baseline

    Vital signs were obtained after the participant had been supine and at rest for 3 minutes and included systolic and diastolic blood pressure, heart rate, temperature, and respiratory rate.

    Time frame: Baseline; from first dose of study drug up to Week 52

  3. Number of Participants With Clinically Significant Changes in Body Weight

    Participants' body weights were measured and recorded.

    Time frame: Baseline; from first dose of study drug up to Week 52

  4. Number of Participants With Post-Baseline Clinically Significant Physical Examinations and Neurological Examinations

    The number of participants with clinically significant changes in physical and neurological examination results post-treatment was documented.

    Time frame: Baseline; from first dose of study drug up to Week 52

  5. Number of Participants With Clinically Significant Post-Baseline Changes in Electrocardiogram (ECG) Values

    12-lead electrocardiogram (ECG) recordings were obtained after the participant had been supine and at rest for at least 3 minutes.

    Time frame: Baseline; from first dose of study drug up to Week 52

  6. Number of Participants With Clinically Significant Changes in Clinical Laboratory Values

    Clinical laboratory tests were performed at scheduled study visits, and the investigator recorded any clinically significant changes.

    Time frame: Baseline; from first dose of study drug up to Week 52

  7. Number of Participants With Clinically Significant Changes in Metabolic Parameter Values

    Clinical laboratory tests were performed at scheduled study visits, and the investigator recorded any clinically significant changes in metabolic parameter values.

    Time frame: Baseline; from first dose of study drug up to Week 52

  8. Number of Participants With Suicide-Related Treatment-Emergent Events Assessed Using the Columbia Suicide Severity Rating Scale (C-SSRS)

    The C-SSRS rates an individual's degree of suicidal ideation (SI) on a scale, ranging from "wish to be dead" to "active suicidal ideation with specific plan and intent." The scale identifies SI severity and intensity, which may be indicative of an individual's intent to commit suicide. C-SSRS SI severity subscale ranges from 0 (no SI) to 5 (active SI with plan and intent).

    Time frame: Baseline; from first dose of study drug up to Week 52

  9. Change From Baseline in Simpson Angus Scale (SAS) Total Score

    The SAS consists of a list of 10 symptoms of parkinsonism. Each item is rated on a 5-point scale, with a score of 0 representing absence of symptoms and a score of 4 representing a severe condition. The SAS total score is the sum of the scores for all 10 items. Baseline was defined as the last value obtained prior to initiation of study drug. Change from baseline for a given endpoint was defined as the value on a given Study Day (Time Point) minus the Baseline Value. Negative changes from Baseline indicate an improvement in symptoms.

    Time frame: Baseline; Weeks 4, 8, 12, 20, 26, 32, 38, 44, and 52

  10. Change From Baseline in Abnormal Involuntary Movement Scale (AIMS) Movement Rating Score

    The Abnormal Involuntary Movement Scale assessment consists of 10 items describing symptoms of dyskinesia. Facial and oral movements (items 1-4), extremity movements (items 5 and 6), and trunk movements (item 7) are observed unobtrusively while the participant is at rest, and the investigator also makes global judgments on the participant's dyskinesias (items 8-10). Each item is rated on a 5-point scale, with a score of 0 representing absence of symptoms (for item 10, no awareness), and a score of 4 indicating a severe condition (for item 10, awareness, severe distress). In addition, the AIMS includes 2 yes/no questions that address the participant's dental status. The AIMS Movement Rating Score is defined as the sum of individual scores from items 1-7, ranging from 0 to 28. A lower score indicates less severe or absent abnormal movements. A negative change in the mean from Baseline indicates improvement in the severity of abnormal involuntary movements.

    Time frame: Baseline; Weeks 4, 8, 12, 20, 26, 32, 38, 44, and 52

  11. Change From Baseline in Barnes Akathisia Rating Scale (BARS) Global Clinical Evaluation Score

    The BARS consists of 4 items related to akathisia. The fourth item, reported here, is the Global Clinical Evaluation Score. The Global Clinical Evaluation Score is evaluated using a 6-point scale, ranging from 0 to 5, with 0 representing absence of symptoms and a score of 5 representing severe akathisia. A negative change from baseline indicates an improvement in symptoms.

    Time frame: Baseline; Weeks 4, 8, 12, 20, 26, 32, 38, 44, and 52

07

Results

Posted Aug 21, 2026

Participant flow

Two groups of participants were included in the study: rollover (who completed treatment in the double-blind, placebo-controlled, Phase 2 efficacy Study CVL-231-2001 or Study CVL-231-2002) and de novo participants (who had stable schizophrenia and were not enrolled in either Phase 2 efficacy study). The study included an up to 15-day Screening Period (de novo participants only), a 52-week Treatment Period, and a 28-day Follow-up Period.

Participant flow — Overall Study
MilestoneCVL-231-2001/2002 Active RolloverCVL-231-2001/2002 Placebo RolloverDe Novo
Started9749552
Completed2519126
Not completed7230426
Withdrew: Adverse event8245
Withdrew: Death001
Withdrew: Lost to follow-up15640
Withdrew: Failure to meet continuation criteria003
Withdrew: Lack of efficacy213
Withdrew: Non-compliance with study schedule013
Withdrew: Non-compliance with study drug7016
Withdrew: Physician decision4012
Withdrew: Study terminated by sponsor44200
Withdrew: Withdrawal of consent301496
Withdrew: Other, not specified227

Outcome measures

PrimaryNumber of Participants With Treatment Emergent Adverse Events (TEAEs) and Treatment Emergent Serious Adverse Events (TESAEs)

An adverse event (AE) is defined as any untoward medical occurrence in a patient or clinical investigation participant administered a pharmaceutical product which does not necessarily have a causal relationship with this treatment. The investigator assesses the relationship of each event to the use of study drug. A serious adverse event (SAE) is an event that results in death, is life-threatening, requires or prolongs hospitalization, results in a congenital anomaly, persistent or significant disability/incapacity or is an important medical event that, based on medical judgment, may jeopardize the participant and may require medical or surgical intervention to prevent any of the outcomes listed above. Treatment-emergent adverse events/treatment-emergent serious adverse events (TEAEs/TESAEs) are defined as any event that began or worsened in severity on or after the first dose of study drug.

Time frame:
From first dose of study drug until 28 days following last dose of study drug (up to Week 56)
Reported as:
Number · number of participants
Number of Participants With Treatment Emergent Adverse Events (TEAEs) and Treatment Emergent Serious Adverse Events (TESAEs)
number of participantsCVL-231-2001/2002 Active RolloverCVL-231-2001/2002 Placebo RolloverDe Novo
Any TEAE3421316
TESAE7235
PrimaryNumber of Participants With Out-of-Range Vital Signs Occurring Post-Baseline

Vital signs were obtained after the participant had been supine and at rest for 3 minutes and included systolic and diastolic blood pressure, heart rate, temperature, and respiratory rate.

Time frame:
Baseline; from first dose of study drug up to Week 52
Reported as:
Count of participants · Participants
Number of Participants With Out-of-Range Vital Signs Occurring Post-Baseline
ParticipantsCVL-231-2001/2002 Active RolloverCVL-231-2001/2002 Placebo RolloverDe Novo
Supine Systolic Blood Pressure < 90 mmHg001
Supine Systolic Blood Pressure 140 - 160 mmHg8234
Supine Systolic Blood Pressure 160 - 200 mmHg105
Orthostatic Change in Systolic Blood Pressure ≥ 20 mmHg decrease1010
Supine Diastolic Blood Pressure 90 - 100 mmHg9439
Supine Diastolic Blood Pressure 100 - 120 mmHg006
Orthostatic Change in Diastolic Blood Pressure ≥ 10 mmHg decrease6222
Supine Heart Rate < 50 bpm206
Supine Heart Rate 50 - 60 bpm144100
Supine Heart Rate 100 - 120 bpm1121
Supine Heart Rate > 120 bpm001
Temperature < 36 °C119
Respiratory Rate < 12 breaths/min111
Respiratory Rate > 20 breaths/min012
PrimaryNumber of Participants With Clinically Significant Changes in Body Weight

Participants' body weights were measured and recorded.

Time frame:
Baseline; from first dose of study drug up to Week 52
Reported as:
Count of participants · Participants
Number of Participants With Clinically Significant Changes in Body Weight
ParticipantsCVL-231-2001/2002 Active RolloverCVL-231-2001/2002 Placebo RolloverDe Novo
≥ 7% decrease18965
≥ 7% increase5547
PrimaryNumber of Participants With Post-Baseline Clinically Significant Physical Examinations and Neurological Examinations

The number of participants with clinically significant changes in physical and neurological examination results post-treatment was documented.

Time frame:
Baseline; from first dose of study drug up to Week 52
Reported as:
Count of participants · Participants
Number of Participants With Post-Baseline Clinically Significant Physical Examinations and Neurological Examinations
ParticipantsCVL-231-2001/2002 Active RolloverCVL-231-2001/2002 Placebo RolloverDe Novo
Any clinically significant physical examination findings214
Any clinically significant neurological examination findings108
PrimaryNumber of Participants With Clinically Significant Post-Baseline Changes in Electrocardiogram (ECG) Values

12-lead electrocardiogram (ECG) recordings were obtained after the participant had been supine and at rest for at least 3 minutes.

Time frame:
Baseline; from first dose of study drug up to Week 52
Reported as:
Count of participants · Participants
Number of Participants With Clinically Significant Post-Baseline Changes in Electrocardiogram (ECG) Values
ParticipantsCVL-231-2001/2002 Active RolloverCVL-231-2001/2002 Placebo RolloverDe Novo
QTcF value > 450 - 480 msec7223
QTcF value > 480 - 500 msec101
QTcF increase from Baseline > 30 - 60 msec201070
QTcF increase from Baseline > 60 msec100
PrimaryNumber of Participants With Clinically Significant Changes in Clinical Laboratory Values

Clinical laboratory tests were performed at scheduled study visits, and the investigator recorded any clinically significant changes.

Time frame:
Baseline; from first dose of study drug up to Week 52
Reported as:
Count of participants · Participants
Number of Participants With Clinically Significant Changes in Clinical Laboratory Values
ParticipantsCVL-231-2001/2002 Active RolloverCVL-231-2001/2002 Placebo RolloverDe Novo
Number of Participants With Clinically Significant Changes in Clinical Laboratory Values5135
PrimaryNumber of Participants With Clinically Significant Changes in Metabolic Parameter Values

Clinical laboratory tests were performed at scheduled study visits, and the investigator recorded any clinically significant changes in metabolic parameter values.

Time frame:
Baseline; from first dose of study drug up to Week 52
Reported as:
Count of participants · Participants
Number of Participants With Clinically Significant Changes in Metabolic Parameter Values
ParticipantsCVL-231-2001/2002 Active RolloverCVL-231-2001/2002 Placebo RolloverDe Novo
Number of Participants With Clinically Significant Changes in Metabolic Parameter Values218
PrimaryNumber of Participants With Suicide-Related Treatment-Emergent Events Assessed Using the Columbia Suicide Severity Rating Scale (C-SSRS)

The C-SSRS rates an individual's degree of suicidal ideation (SI) on a scale, ranging from "wish to be dead" to "active suicidal ideation with specific plan and intent." The scale identifies SI severity and intensity, which may be indicative of an individual's intent to commit suicide. C-SSRS SI severity subscale ranges from 0 (no SI) to 5 (active SI with plan and intent).

Time frame:
Baseline; from first dose of study drug up to Week 52
Reported as:
Count of participants · Participants
Number of Participants With Suicide-Related Treatment-Emergent Events Assessed Using the Columbia Suicide Severity Rating Scale (C-SSRS)
ParticipantsCVL-231-2001/2002 Active RolloverCVL-231-2001/2002 Placebo RolloverDe Novo
Treatment-Emergent Suicidal Ideation Compared to Recent History0213
Treatment-Emergent Serious Suicidal Ideation Compared to Recent History013
Emergence of Serious Suicidal Ideation Compared to Recent History003
Emergence of Suicidal Behavior Compared to all Prior History001
PrimaryChange From Baseline in Simpson Angus Scale (SAS) Total Score

The SAS consists of a list of 10 symptoms of parkinsonism. Each item is rated on a 5-point scale, with a score of 0 representing absence of symptoms and a score of 4 representing a severe condition. The SAS total score is the sum of the scores for all 10 items. Baseline was defined as the last value obtained prior to initiation of study drug. Change from baseline for a given endpoint was defined as the value on a given Study Day (Time Point) minus the Baseline Value. Negative changes from Baseline indicate an improvement in symptoms.

Time frame:
Baseline; Weeks 4, 8, 12, 20, 26, 32, 38, 44, and 52
Reported as:
Mean · units on a scale
Change From Baseline in Simpson Angus Scale (SAS) Total Score
units on a scaleCVL-231-2001/2002 Active RolloverCVL-231-2001/2002 Placebo RolloverDe Novo
Week 4-0.1 ± 0.46-0.2 ± 0.870.0 ± 0.46
Week 80.0 ± 0.53-0.2 ± 0.910.0 ± 0.36
Week 12-0.1 ± 0.45-0.2 ± 0.920.0 ± 0.42
Week 20-0.1 ± 0.69-0.2 ± 1.020.0 ± 0.44
Week 26-0.1 ± 0.63-0.2 ± 0.990.0 ± 0.55
Week 32-0.2 ± 0.56-0.2 ± 1.030.0 ± 0.43
Week 38-0.2 ± 0.63-0.3 ± 1.040.0 ± 0.41
Week 44-0.2 ± 0.590.0 ± 1.600.0 ± 0.42
Week 520.0 ± 0.29-0.3 ± 1.150.0 ± 0.48
PrimaryChange From Baseline in Abnormal Involuntary Movement Scale (AIMS) Movement Rating Score

The Abnormal Involuntary Movement Scale assessment consists of 10 items describing symptoms of dyskinesia. Facial and oral movements (items 1-4), extremity movements (items 5 and 6), and trunk movements (item 7) are observed unobtrusively while the participant is at rest, and the investigator also makes global judgments on the participant's dyskinesias (items 8-10). Each item is rated on a 5-point scale, with a score of 0 representing absence of symptoms (for item 10, no awareness), and a score of 4 indicating a severe condition (for item 10, awareness, severe distress). In addition, the AIMS includes 2 yes/no questions that address the participant's dental status. The AIMS Movement Rating Score is defined as the sum of individual scores from items 1-7, ranging from 0 to 28. A lower score indicates less severe or absent abnormal movements. A negative change in the mean from Baseline indicates improvement in the severity of abnormal involuntary movements.

Time frame:
Baseline; Weeks 4, 8, 12, 20, 26, 32, 38, 44, and 52
Reported as:
Mean · units on a scale
Change From Baseline in Abnormal Involuntary Movement Scale (AIMS) Movement Rating Score
units on a scaleCVL-231-2001/2002 Active RolloverCVL-231-2001/2002 Placebo RolloverDe Novo
Week 40.0 ± 0.23-0.1 ± 0.360.0 ± 0.58
Week 80.0 ± 0.410.0 ± 0.000.0 ± 0.56
Week 120.0 ± 0.130.0 ± 0.000.0 ± 0.55
Week 200.0 ± 0.150.1 ± 0.590.0 ± 0.49
Week 260.0 ± 0.150.0 ± 0.190.0 ± 0.68
Week 32-0.1 ± 0.320.0 ± 0.000.0 ± 0.61
Week 380.1 ± 0.530.0 ± 0.000.0 ± 0.68
Week 440.0 ± 0.000.0 ± 0.000.0 ± 0.48
Week 520.0 ± 0.200.1 ± 0.460.0 ± 0.58
PrimaryChange From Baseline in Barnes Akathisia Rating Scale (BARS) Global Clinical Evaluation Score

The BARS consists of 4 items related to akathisia. The fourth item, reported here, is the Global Clinical Evaluation Score. The Global Clinical Evaluation Score is evaluated using a 6-point scale, ranging from 0 to 5, with 0 representing absence of symptoms and a score of 5 representing severe akathisia. A negative change from baseline indicates an improvement in symptoms.

Time frame:
Baseline; Weeks 4, 8, 12, 20, 26, 32, 38, 44, and 52
Reported as:
Mean · units on a scale
Change From Baseline in Barnes Akathisia Rating Scale (BARS) Global Clinical Evaluation Score
units on a scaleCVL-231-2001/2002 Active RolloverCVL-231-2001/2002 Placebo RolloverDe Novo
Week 40.0 ± 0.200.0 ± 0.370.0 ± 0.22
Week 80.0 ± 0.170.0 ± 0.000.0 ± 0.17
Week 120.0 ± 0.000.0 ± 0.000.0 ± 0.22
Week 200.0 ± 0.150.1 ± 0.380.0 ± 0.21
Week 260.0 ± 0.150.0 ± 0.190.0 ± 0.32
Week 320.0 ± 0.160.0 ± 0.000.0 ± 0.23
Week 380.0 ± 0.180.0 ± 0.000.0 ± 0.21
Week 440.0 ± 0.000.0 ± 0.000.0 ± 0.15
Week 520.0 ± 0.000.0 ± 0.000.0 ± 0.17

Adverse events

Collected over All-cause mortality and adverse events reported from time informed consent was signed to end of the study. Median follow-up was 154 days for the CVL-231-2001/2002 Active Rollover group, 267 days for the CVL-231-2001/2002 Placebo Rollover group, and 213.5 days for the De Novo group.. Non-serious events are listed at a 2% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
CVL-231-2001/2002 Active Rollover1/97 (1%)7/97 (7.2%)24/97 (24.7%)
CVL-231-2001/2002 Placebo Rollover0/49 (0%)2/49 (4.1%)21/49 (42.9%)
De Novo2/552 (0.4%)35/552 (6.3%)212/552 (38.4%)
Most frequent serious events
Showing 10 of 19
Most frequent serious events
EventCVL-231-2001/2002 Active RolloverCVL-231-2001/2002 Placebo RolloverDe Novo
SCHIZOPHRENIAPsychiatric disorders3/970/4922/552
SYNCOPENervous system disorders0/971/490/552
PSYCHOTIC DISORDERPsychiatric disorders1/971/491/552
OVERDOSEInjury, poisoning and procedural complications1/970/490/552
TIBIA FRACTUREInjury, poisoning and procedural complications1/970/490/552
RHABDOMYOLYSISMusculoskeletal and connective tissue disorders1/970/490/552
SCHIZOAFFECTIVE DISORDERPsychiatric disorders1/970/490/552
ACUTE KIDNEY INJURYRenal and urinary disorders1/970/490/552
PULMONARY EMBOLISMRespiratory, thoracic and mediastinal disorders1/970/491/552
AGITATIONPsychiatric disorders0/970/492/552
Most frequent other events
Showing 10 of 39
Most frequent other events
EventCVL-231-2001/2002 Active RolloverCVL-231-2001/2002 Placebo RolloverDe Novo
HEADACHENervous system disorders2/975/4934/552
SOMNOLENCENervous system disorders1/971/4930/552
DRY MOUTHGastrointestinal disorders0/971/4929/552
DIZZINESSNervous system disorders1/970/4929/552
INSOMNIAPsychiatric disorders1/970/4929/552
WEIGHT INCREASEDInvestigations5/972/4920/552
WEIGHT DECREASEDInvestigations4/971/4915/552
FALLInjury, poisoning and procedural complications0/972/490/552
NAUSEAGastrointestinal disorders1/971/4919/552
BACK PAINMusculoskeletal and connective tissue disorders3/971/499/552

Baseline characteristics

Intent-to-treat (ITT): All participants who were enrolled in the trial

Age, Continuous
Age, Continuous(years)CVL-231-2001/2002 Active RolloverCVL-231-2001/2002 Placebo RolloverDe NovoTotal
Mean44.5 ± 11.4445.4 ± 11.8145.1 ± 12.0845.0 ± 11.96
Sex: Female, Male
Sex: Female, Male(Participants)CVL-231-2001/2002 Active RolloverCVL-231-2001/2002 Placebo RolloverDe NovoTotal
Female2715178220
Male7034374478
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)CVL-231-2001/2002 Active RolloverCVL-231-2001/2002 Placebo RolloverDe NovoTotal
Hispanic or Latino2510111146
Not Hispanic or Latino7039440549
Unknown or Not Reported2013
Race (NIH/OMB)
Race (NIH/OMB)(Participants)CVL-231-2001/2002 Active RolloverCVL-231-2001/2002 Placebo RolloverDe NovoTotal
American Indian or Alaska Native1001
Asian1146
Native Hawaiian or Other Pacific Islander2013
Black or African American4520190255
White4827356431
More than one race0112
Unknown or Not Reported0000
08

Study locations

85 sites
  • Phoenix, Arizona
    Phoenix, Arizona 85012-2707, United States
  • Bryant, Arkansas
    Bryant, Arkansas 72022-9252, United States
  • Little Rock, Arkansas
    Little Rock, Arkansas 72211-3702, United States
  • Anaheim, California
    Anaheim, California 92805-5854, United States
  • Bellflower, California
    Bellflower, California 90706-7079, United States
  • Culver City, California
    Culver City, California 90230-6632, United States
  • Garden Grove, California
    Garden Grove, California 92845-2506, United States
  • La Habra, California
    La Habra, California 90631-3842, United States
  • Lemon Grove, California
    Lemon Grove, California 91945-2956, United States
  • Montclair, California
    Montclair, California 91763-2231, United States
  • Orange,California
    Orange, California 92868-4447, United States
  • Pico Rivera, California
    Pico Rivera, California 90660-4920, United States
  • Riverside, California
    Riverside, California 92506-3237, United States
  • San Diego, California
    San Diego, California 92103-2209, United States
  • San Diego, California
    San Diego, California 92121, United States
  • San Diego, California
    San Diego, California 92123, United States
  • Sherman Oaks, California
    Sherman Oaks, California 91403-1747, United States
  • Torrance, California
    Torrance, California 90502-4432, United States
  • Walnut Creek, California
    Walnut Creek, California 94549, United States
  • New Haven, Connecticut
    New Haven, Connecticut 06519-1109, United States
  • Bonita Springs,Florida
    Bonita Springs, Florida 34134-4154, United States
  • Fort Myers, Florida
    Fort Myers, Florida 33901-3711, United States
  • Hialeah, Florida
    Hialeah, Florida 33012-4648, United States
  • Hialeah, Florida
    Hialeah, Florida 33016-1814, United States
  • Miami, Florida
    Miami, Florida 33122-1335, United States
  • Miami, Florida
    Miami, Florida 33125-5114, United States
  • Miami, Florida
    Miami, Florida 33155, United States
  • Miami Lakes, Florida
    Miami Lakes, Florida 33016-1553, United States
  • Miami Lakes, Florida
    Miami Lakes, Florida 33016, United States
  • Miami Springs, Florida
    Miami Springs, Florida 33166-7225, United States
  • Oakland Park, Florida
    Oakland Park, Florida 33334-4135, United States
  • West Palm Beach, Florida
    West Palm Beach, Florida 33407-2015, United States
  • Atlanta, Georgia
    Atlanta, Georgia 30318-3102, United States
  • Atlanta, Georgia
    Atlanta, Georgia 30328-4018, United States
  • Atlanta, Georgia
    Atlanta, Georgia 30331, United States
  • Decatur, Georgia
    Decatur, Georgia 30030-3438, United States
  • Savannah,Georgia
    Savannah, Georgia 31405-5702, United States
  • Berwyn, Illinois
    Berwyn, Illinois 60402-2248, United States
  • Chicago, Illinois
    Chicago, Illinois 60611-3478, United States
  • Chicago, Illinois
    Chicago, Illinois 60622-1702, United States
  • Chicago, Illinois
    Chicago, Illinois 60623, United States
  • Chicago, Illinois
    Chicago, Illinois 60640-5017, United States
  • Chicago, Illinois
    Chicago, Illinois 60641-4023, United States
  • Marrero, Louisiana
    Marrero, Louisiana 70072-3083, United States
  • Shreveport, Louisiana
    Shreveport, Louisiana 71101-4603, United States
  • Gaithersburg, Maryland
    Gaithersburg, Maryland 20877-1409, United States
  • Flowood, Mississippi
    Flowood, Mississippi 39232-8016, United States
  • Las Vegas, Nevada
    Las Vegas, Nevada 89102-1972, United States
  • Berlin, New Jersey
    Berlin, New Jersey 08009, United States
  • Cedarhurst, New York
    Cedarhurst, New York 11516-1905, United States
  • New York, New York
    New York, New York 10036-4811, United States
  • Staten Island, New York
    Staten Island, New York 10314-1607, United States
  • Charlotte, North Carolina
    Charlotte, North Carolina 28211-4849, United States
  • North Canton, Ohio
    North Canton, Ohio 44718-2567, United States
  • Oklahoma City, Oklahoma
    Oklahoma City, Oklahoma 73102-1018, United States
  • Franklin,Tennessee
    Franklin, Tennessee 37067-5967, United States
  • Austin, Texas
    Austin, Texas 78754-5122, United States
  • DeSoto, Texas
    DeSoto, Texas 75115-2066, United States
  • Houston, Texas
    Houston, Texas 77043, United States
  • Houston, Texas
    Houston, Texas 77074, United States
  • Plano, Texas
    Plano, Texas 75093-0010, United States
  • Richardson, Texas
    Richardson, Texas 75080-3764, United States
  • Sofia, Sofia-Grad
    Sofia, Sofia-Grad 1202, Bulgaria
  • Sofia, Sofia-Grad
    Sofia, Sofia-Grad 1407, Bulgaria
  • Sofia, Sofia-Grad
    Sofia, Sofia-Grad 1431, Bulgaria
  • Sofia, Sofia-Grad
    Sofia, Sofia-Grad 1510, Bulgaria
  • Sofia, Sofia-Grad
    Sofia, Sofia-Grad 1606, Bulgaria
  • Sofia, Sofia-Grad
    Sofia, Sofia-Grad 1680, Bulgaria
  • Pazardzhik, Pazardzhik
    Pazardzhik, 4400, Bulgaria
  • Pleven, Pleven
    Pleven, 5800, Bulgaria
  • Sliven, Sliven
    Sliven, 8800, Bulgaria
  • Stara Zagora, Stara Zagora
    Stara Zagora, 6003, Bulgaria
  • Varna, Varna
    Varna, 9000, Bulgaria
  • Veliko Tarnovo, Veliko Tarnovo
    Veliko Tarnovo, 5000, Bulgaria
  • Vratsa, Vratsa
    Vratsa, 3000, Bulgaria
  • Kalocsa, Bács-Kiskun
    Kalocsa, Bács-Kiskun county 6300, Hungary
  • Gyor, Gyor-Moson-Sopron
    Győr, Győr-Moson-Sopron 9024, Hungary
  • San Juan, Puerto Rico
    San Juan, 918, Puerto Rico
  • San Juan, Puerto Rico
    San Juan, 926, Puerto Rico
  • Ivano Frankivsk, Ivano Frankivsk
    Ivano-Frankivsk, Ivano-Frankivsk Oblast 76011, Ukraine
  • Lviv, L'vivs'ka Oblast
    Lviv, Lviv Oblast 79021, Ukraine
  • Kropyvnytskyi, Kropyvnytskyi
    Kropyvnytskyi, 25491, Ukraine
  • Kyiv, Kyïv
    Kyiv, 04080, Ukraine
  • Smila, Smila
    Smila, 20708, Ukraine
  • Vinnytsia, Vinnytsia
    Vinnytsia, 21018, Ukraine
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: No

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Sep 2022 to primary completion in Jun 2025, 33 months.

Results were first posted in Aug 2026, 1 year 1 month after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 29, 2022
First posted
Jul 5, 2022
StartActual
Sep 1, 2022
Primary completionActual
Jun 25, 2025
CompletionActual
Jun 25, 2025
Results first posted
Aug 21, 2026
Last update
Aug 21, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 21, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT05443724
Lead sponsor
AbbVie
Responsible party
Sponsor
First posted
Jul 5, 2022
Start date
Sep 1, 2022
Primary completion
Jun 25, 2025
Completion
Jun 25, 2025
Results posted
Aug 21, 2026
Last update
Aug 21, 2026

Study contacts

ABBVIE INC.
study director · AbbVie

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is terminated, as verified in Aug 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Emraclidine

Start the discussion